Navigation Links
AGA Medical Announces Management Transition
Date:6/20/2008

MINNEAPOLIS, June 20 /PRNewswire/ -- AGA Medical Holdings, Inc. ("AGA Medical" or "AGA") announced today a transition of responsibilities in its senior management team.

Franck Gougeon has decided to transition from his day-to-day role as President and CEO of AGA to focus his efforts on strategic planning for AGA's future. Mr. Gougeon will remain a member of the AGA's Board of Directors and will Chair a newly formed committee of the Board, the Corporate Development Committee. The Committee has been chartered to focus on AGA's long-range strategies in a number of areas, including product development and planning and AGA strategic human resource planning and development.

Tommy Thompson, Chairman of the Board for AGA, commented, "Franck Gougeon has played a critical role in the development of AGA. Under his leadership, the Company has expanded operations and now sells in over 100 countries. His close work with Dr. Amplatz, a co-founder of AGA Medical along with Franck, has enabled the company to build a reputation for innovation in the field of minimally invasive repair of structural heart defects."

Mr. Thompson continued, "In his new role, Franck will continue to work closely with Dr. Amplatz on new product development and will help develop a longer-term vision for the company. He has developed relationships with leading cardiologists around the world, and we plan to work with Franck to leverage those relationships on AGA's behalf. I have enjoyed working with Franck in his role as AGA's CEO, and I look forward to our continued relationship as he moves into this important new role. I anticipate that AGA and the Board will continue to benefit greatly from his experience and leadership in these key areas."

Franck Gougeon co-founded AGA with Dr. Kurt Amplatz in 1995. He was named President and CEO in July 2005 following a successful recapitalization and investment in the company by Welsh Carson Anderson and Stowe. Under Mr. Gougeon's stewardship, the Company has grown to approximately $150 million in revenue in 2007 and over 300 employees with direct operations overseas in 9 countries and offices in Birmingham, UK, Frankfurt, Germany and Madrid, Spain. Mr. Gougeon continues to be a major shareholder in AGA.

John Barr, who has served as Chief Operating Officer of AGA since September 2005 under Franck Gougeon, has been named President and CEO of AGA.

Franck Gougeon commented, "John and I have worked closely in the past few years to build the Company and strengthen the management team. He is the right person to take this company forward, and I look forward to working with him on a smooth and effective transition and in my new role with AGA. I also look forward to continuing my work with Dr. Amplatz and AGA to develop and commercialize innovative devices to treat both structural heart and vascular defects."

Mr. Barr's prior experience includes serving as CEO of V.I. Technologies, a development stage company, President of North American Operations and a member of the Board of Directors for Haemonetics Corporation and in a variety of roles at Baxter Healthcare. Mr. Barr has a B.S. in Bioengineering from the University of Pennsylvania and an MBA from the Kellogg School of Management at Northwestern University.

ABOUT AGA MEDICAL: AGA Medical, based in Plymouth, Minnesota (just outside Minneapolis) is a leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, AGA develops and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. More than 800 articles have been published in medical publications that support the benefits of AGA devices, including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient. AGA l devices have received regulatory approval and are marketed in 101 countries. For more information visit http://www.amplatzer.com.


'/>"/>
SOURCE AGA Medical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Rehabilitation Hospital Team Calls Work of US Armys Europe Regional Medical Command Impressive
2. Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008
3. BioForm Medical to Present at the 2008 Jefferies Second Annual Healthcare Conference
4. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
5. Oakwood Southshore Medical Center Delivers on Promise of Enhanced Community Healthcare
6. Regence Pilot Shows Affordability of Electronic Medical Records
7. System constraints forcing Canadian physicians to become medical brokers in prioritizing
8. Corn Refiners Association Applauds American Medical Association Decision on High Fructose Corn Syrup
9. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
10. China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and Technology Institute
11. Shanghai Medical Technology Co., First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology: